TFK-1人胆管癌细胞
BLUEFBIO™ Product Sheet
细胞名称 |
TFK-1人胆管癌细胞 |
|
|
货物编码 |
BFN60808817 |
||
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
细胞数量 |
1x10^6 |
1x10^6 |
|
保存温度 |
37℃ |
-198℃ |
|
运输方式 |
常温保温运输 |
干冰运输 |
|
安全等级 |
1 |
||
用途限制 |
仅供科研 2类 |
培养体系 |
90%DMEM+10%FBS+1%三抗 |
||
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
简介 |
TFK-1人胆管癌细胞取自63岁男性供体。该细胞源于DSMZ |
||
注释 |
Doubling time: ~37 hours, at 40th passage (PubMed=8693487); ~40 hours (DSMZ). Omics: Deep exome analysis. Misspelling: TFKK-1; PubMed=22490663 supplementary figure 2. |
||
基因突变 |
/ |
||
HLA信息 |
/ |
||
STR信息 |
Amelogenin X,Y CSF1PO 10 D5S818 9,12 D7S820 10 (DSMZ) 10,11 (RCB; TKG) D13S317 14 D16S539 9 TH01 6 TPOX 8 vWA 14,17 |
||
参考文献 |
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T. Screening the p53 status of human cell lines using a yeast functional assay. Mol. Carcinog. 19:243-253(1997)
PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122 Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem. Biophys. Res. Commun. 421:98-104(2012)
CLPUB00275 Zach S., Birgin E., Ruckert F. Primary cholangiocellular carcinoma cell lines. J. Stem Cell Res. Transplant. 2:1013-1013(2015)
PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442 Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., Bardeesy N. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 6:727-739(2016)
PubMed=31077409; DOI=10.1002/hep.30704 Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology 70:1614-1630(2019) |